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Abstract
Background—Estimates of influenza- and respiratory syncytial virus (RSV)-associated 
mortality burden are important to guide policy for control. Data are limited on the contribution of 
out-of-hospital deaths to this mortality.
Methods—We modeled excess mortality attributable to influenza and RSV infection by applying 
regression models to weekly deaths from national vital statistics from 2009 through 2013, using 
influenza and RSV laboratory surveillance data as covariates. We fitted separate models for in- and 
out-of-hospital deaths.
Results—There were 509 791 average annual deaths in South Africa, of which 44% (95% 
confidence interval [CI] 43%–45%) occurred out-of-hospital. Seasonal influenza and RSV all-
cause mortality rates were 23.0 (95% CI 11.0–30.6) and 13.2 (95% CI 6.4–33.8) per 100 000 
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population annually (2.3% [95%CI 2.3%–2.4%] and 1.3% [95% CI 1.2%–1.4%] of all deaths 
respectively). The peak mortality rate was in individuals aged ≥75 years (386.0; 95% CI 176.5–
466.3) for influenza and in infants (143.4; 95% CI 0–194.8) for RSV. Overall, 63% (95% CI 62%–
−65%) of seasonal influenza and 48% (95% CI 47%–49%) of RSV-associated deaths occurred 
out-of-hospital. Among children aged <5 years, RSV-associated deaths were more likely to occur 
in-hospital, whereas influenza-associated deaths were more likely to occur out-of-hospital. The 
mortality rate was 6.7 (95% CI 6.4–33.8) in the first influenza A(H1N1)pdm09 wave in 2009 and 
20.9 (95% CI 6.4–33.8) in the second wave in 2011, with 30% (95% CI 29%–32%) of 
A(H1N1)pdm09-associated deaths in 2009 occurring out-of-hospital.
Discussion—More than 45% of seasonal influenza- and RSV-associated deaths occur out-of-
hospital in South Africa. These data suggest that hospital-based studies may substantially 
underestimate mortality burden.
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It is important to quantify the burden of influenza- and respiratory syncytial virus (RSV)-
associated mortality in order to guide prioritization of interventions. Data on influenza- and 
RSV-associated mortality from low- and middle-income countries and especially in Africa 
are limited [1]. Human immunodeficiency virus (HIV) is an important risk factor for 
influenza- and RSV-associated mortality in South Africa, with a national HIV prevalence of 
12.2% in 2012 [2–4]. South Africa has published estimates of influenza- and RSV-
associated mortality, but these do not include the years following the global emergence of 
influenza A(H1N1)pdm09 in 2009 [5, 6]. Factors that could have impacted influenza- and 
RSV-associated mortality in South Africa since 2009 include recent improvements in the 
prevention and treatment of HIV and introduction of the pneumococcal conjugate vaccine 
into routine immunisation programme in 2009 [7–9]. In addition, influenza vaccine became 
available through publically funded programmes in 2010, with approximately one million 
doses distributed annually.
Approximately 44% of deaths in South Africa occur outside of the hospital [10]. An 
understanding of the proportion of influenza- and RSV-associated deaths occurring outside 
of the hospital is important for the interpretation of global and regional estimates of 
influenza and RSV-associated mortality [11]. Out-of-hospital deaths will be missed in 
traditional hospital-based influenza surveillance programs, potentially leading to 
underestimation of influenza-associated mortality burden [4]. Quantification of the 
proportion out-of-hospital deaths can provide multipliers to account for this.
Influenza A(H1N1)pdm09-associated mortality in 2009 followed the age shift described in 
previous pandemics predominantly affecting individuals aged <65 years [11]. In some 
settings the second wave of influenza A(H1N1)pdm09 has been suggested to have been 
associated with a greater mortality burden than the first wave [12]. It is unclear how large the 
burden of the second wave of influenza A(H1N1)pdm09 was in Africa and whether the 
classic “pandemic age shift” was observed in subsequent waves.
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We aimed to estimate the rate of influenza- and RSV-associated excess deaths in- and out-of-
hospital in South Africa from 2009 to 2013 by age group. In addition, we aimed to estimate 
age-specific excess mortality associated with influenza A(H1N1)pdm09 and describe the 
burden and age distribution of deaths between successive pandemic waves.
METHODS
Sources of Data
We obtained data on underlying causes of death and population denominators from Statistics 
South Africa from 2009 to 2013 [10, 13]. We used the International Classification of 
Diseases, Tenth Revision (ICD-10) codes to compile age-specific (<1, 1–4,5–19, 20–44, 45–
64, 65–74, and ≥75 years) weekly mortality time series for all-cause (ICD-10: any), all-
respiratory (ICD-10: J00–J99), all-circulatory (ICD-10: I00–I99) as well as pneumonia and 
influenza (P&I) (ICD-10: J10–J18; a subset of all-respiratory) deaths. Place of death is 
reported in the vital statistics data set [10]. We obtained influenza virus types and subtypes 
and RSV data from severe acute respiratory illness surveillance at 5 sites [3].
Estimation of Influenza- and Respiratory Syncytial Virus-associated Mortality
To estimate influenza virus type/subtype- and RSV-associated mortality, we fitted age-
specific regression models to the rate of weekly deaths, using a semiparametric generalized 
additive model. We included independent variables for each influenza virus type/subtype and 
RSV for each year. A natural cubic smoothing spline of weeks as the non-parametric 
variable was included. The spline accounts and adjusts for time and trend in non-influenza 
associated mortality in the model. The number of nodes was selected using the Akaike 
Information Criteria. This model was found to provide an improved fit for influenza-
associated mortality compared with more conventional modelling approaches [14].
The model is provided below:
(1)
where E(mortality rate) is the expected respiratory mortality rate, t was the sequential week 
number of the weekly time series, Influenza A(H1N1)pdm09 is the proxy for influenza 
A(H1N1) pdm09, Influenza A(H3N2) is the proxy for influenza A(H3N2), Influenza B is 
the proxy for influenza B, RSV is the proxy for RSV, spline is the spline curve for t and is 
specified with 31 degrees of freedom, which achieved a degree of control for autocorrelation 
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(<0.2). One degree of freedom is allocated to the parametric linear time variable (β1t) and 
the remaining degrees of freedom are distributed at 6 per year for the spline [14]. The model 
correlates changes in influenza and RSV detection to changes in number of deaths over time 
and attributes influenza- and RSV-associated deaths over total death above an estimated 
mortality baseline.
Separate models were fitted for each age group and cause of death. We estimated the age-
specific excess mortality associated with influenza virus types/subtypes and RSV each week 
by subtracting an expected baseline from the weekly mortality predictions of the model. The 
baseline was obtained by setting the relevant viral covariates to 0 (i.e., to obtain a baseline 
for influenza, we set the seasonal influenza proxy to 0 for each type/subtype). Annual excess 
mortality was estimated as the sum of the weekly excess mortality for each year. Negative 
estimates were not set to zero. For the estimation of seasonal influenza-associated mortality 
we included influenza A(H1N1) pdm09-associated deaths after 2009 as seasonal influenza-
associated deaths. As a validation, we estimated the excess mortality associated with cancer 
deaths (ICD-10 C00.0–C97), which are not expected to vary with influenza and RSV 
circulation [15].
For the estimation of in- and out-of-hospital mortality we fitted separate age- and cause of 
death-specific models for in- and out-of-hospital deaths as recorded in the vital statistic data. 
We restricted the analysis of in- and out-of-hospital deaths to the broad groups of all-cause, 
all-circulatory and all-respiratory because we felt that a specific ICD code of pneumonia and 
influenza was unreliable for out-of-hospital deaths [10]. Data on the location of death were 
missing for 20% of individuals overall, 14% of respiratory deaths and 14% of circulatory 
deaths. We adjusted the final excess mortality estimates to account for missing data 
assuming that the percent of deaths in- and out-of-hospital was similar in those with missing 
data to those with available data.
We obtained the 95% confidence interval (CI) for the estimated excess mortality using 
bootstrap resampling on blocks of calendar years over 1000 replications [5, 6]. For each 
resampled dataset we refitted the regression model and the 95% CI were obtained from the 
2.5th and 97.5th percentiles of the estimated influenza- and RSV-associated mortality from 
the 1000 resampled data sets. The statistical analysis was implemented using STATA version 
14 (StataCorp, College Station, Texas).
Ethics
Because this analysis used only publicly available mortality data and de-identified and 
aggregated laboratory data, the study was considered to be exempt from human subjects’ 
review.
RESULTS
Deaths and Mortality Rates
The population of South Africa increased from 50 020 918 in 2009 to 53 192 216 in 2013, 
with approximately 10% of individuals aged <5 years and 5% aged ≥65 years. From 2009 
through 2013, a mean of 509 791 deaths occurred annually, of which 109 032 (21%) were 
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attributable to respiratory and 123 453 (24%) to circulatory causes (Supplementary Table 1). 
The mean annual mortality rate per 100 000 for all-cause death was highest in individuals 
aged ≥75 years, 65–74 years, and <1 year. All-cause deaths rates per 100 000 population 
declined by 25% from 1141 in 2009 to 858 in 2013. The largest reductions were in 
individuals aged 20–44 years (34%) and <1 year (32%) and the smallest in individuals aged 
≥65 years (4%). Deaths peaked seasonally each winter (Supplementary Figure 1).
Influenza and Respiratory Syncytial Virus Surveillance
A mean of 4378 (range 3002–5204) specimens were tested for influenza and RSV annually 
with an annual average of 8% (95% confidence interval (CI) 7%–8%) and 15% (95% CI 
14%–16%) testing positive for influenza and RSV respectively. The influenza season peaked 
between June and August (winter) (Figure 1A). In 2009, influenza A(H3N2) peaked in June 
followed by influenza A(H1N1)pdm09 which peaked in August. RSV peak activity was 
observed between March and May (autumn).
Seasonal Influenza and Respiratory Syncytial Virus-associated Deaths
For seasonal influenza-associated all-cause deaths, the highest mortality rate per 100 000 
population was in individuals aged ≥75 years (386.0; 95% CI: 176.5–466.3), followed by 
infants (87.3; 95% CI: 5.2–118.5) (Table 1, Supplementary Table 2, Supplementary Figure 
2). For RSV-associated deaths, the peak mortality rate was in infants (143.4; 95% CI: 0–
194.8), followed by individuals aged ≥75 years (81.7; 95% CI: 68.8–337.9). Influenza-
associated mortality was highest for influenza A(H3N2), followed by influenza 
A(H1N1)pdm09 and influenza B (Supplementary Table 3).
Rates of influenza-associated circulatory deaths were highest in individuals aged ≥75 (183.9; 
95% CI: 81.2–224.7) (Table 1). Influenza-associated respiratory death rates were highest in 
the ≥75 years age group (115.7; 95% CI: 36.1–140.9), followed by <1 year (33.6; 95% CI: 
25.7–45.1), with a similar pattern for P&I deaths.
Similar to influenza, rates of RSV-associated circulatory deaths were highest in individuals 
aged ≥75 (41.3; 95 CI: 36.0–189.0). RSV-associated respiratory deaths were highest in 
infants (42.0; 95% CI: 0.0–63.9) and ≥75 years (16.0; 95% CI: 13.0–88.1) age groups, with 
a similar pattern for P&I deaths.
An estimated 3.7% and 1.4% of all annual respiratory deaths were associated with influenza 
and RSV respectively (4.6% and 6.0% in children aged <5 years for influenza and RSV 
respectively)(Supplementary Table 2). We did not estimate any significant excess cancer 
deaths associated with influenza or RSV (data not shown).
Deaths Associated With Influenza A(H1N1)pdm09
We estimated that there were 3460 (95% CI: 3010–6572) deaths associated with the first 
wave of influenza A(H1N1)pdm09 in 2009, 10 753 (95% CI: 2922–14 489) deaths in the 
second wave in 2011 and 5938 (95% CI: 2465–8573) in the 3rd wave in 2013 
(Supplementary Table 4). The proportion of deaths in the extremes of age (<1 year and ≥75 
years) increased from 5% in 2009 to 38% in 2011 and 25% in 2013, with concomitant 
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reductions in the percent of deaths in older children and young adults (Table 2, 
Supplementary Table 4, Figure 2, Supplementary Figures 3–4). Circulatory deaths accounted 
for 15% (525/3460) of all deaths in 2009, 30% (3228/10753) in 2011 and 19% (1125/5938) 
in 2013.
Influenza- and Respiratory Syncytial Virus-associated in- and out-of-hospital Deaths
Overall, 44% (95% CI: 43%–45%) of all-cause deaths, 45% (95% CI: 44%–46%) of 
circulatory deaths and 38% (95% CI: 37–39) of respiratory deaths occurred out of the 
hospital (Table 3, Supplementary Table 5). Among children aged <5 years, in-hospital 
deaths peaked between weeks 1 and 21 (January to May), coinciding with the period of RSV 
circulation, whereas out-of-hospital deaths peaked from weeks 17 to 29 (May to July), 
coinciding with the peak in influenza virus circulation (Figure 1B). In individuals aged ≥5 
years the timing of the peak of in- and out-of-hospital deaths was similar and coincided with 
the period of influenza virus circulation (Figure 1C).
Overall, 48% (95% CI: 47%–49%) of RSV-associated and 63% (95% CI: 62%–64%) of 
influenza-associated all-cause deaths occurred outside of the hospital (Table 3). For RSV-
associated deaths, proportionately fewer deaths occurred out of the hospital compared to the 
overall percent of out-of-hospital all-cause deaths among the <5 years age group; for 
example, 26% (95% CI: 24–28) of RSV-associated all-cause deaths occurred out-of-hospital 
vs. 41% (95% CI: 40%–42%) of all-cause deaths overall (risk ratio (RR) 0.6; 95% CI: 0.6–
0.7). In contrast, in the ≥5 years age group more or a similar proportion of RSV-associated 
deaths occurred outside of the hospital compared to all deaths (for all-cause deaths 56% 
(95% CI: 55%–58%) of RSV-associated deaths out-of-hospital vs. 44% (95% CI: 43%–
45%) of all deaths RR 1.3; 95% CI:1.2–1.3).
For seasonal influenza-associated deaths, the percent of out-of-hospital deaths was greater 
than or similar to the overall percent of out-of-hospital deaths for all-cause of death and age 
groups (Table 3). In contrast, for influenza A(H1N1)pdm09 in 2009, for all-cause of death 
groups, proportionately fewer deaths occurred out-of-hospital.
DISCUSSION
We have estimated that from 2009 through 2013 there were approximately 11 800 annual 
seasonal influenza- and 6800 RSV-associated deaths in South Africa, with influenza 
accounting for approximately 4% of respiratory deaths in all ages, and RSV for 6% in 
children aged <5 years. The peak rates of influenza-associated mortality were in older 
adults, whereas peak rates of RSV-associated mortality were in infants. The mortality impact 
of the 2009 influenza A(H1N1)pdm09 pandemic was greater in the second than the first 
wave, associated with a shift in the age distribution of mortality towards the extremes of age. 
More than 45% of influenza- and RSV-associated deaths occurred outside of the hospital.
We provide updated estimates of influenza- and RSV-associated mortality for South Africa 
in the period during and following the 2009 influenza pandemic. Compared to previous 
estimates, these estimates were obtained using a different modeling approach incorporating 
weekly (as opposed to monthly) data and including separate estimation of influenza-
Cohen et al. Page 6
Clin Infect Dis. Author manuscript; available in PMC 2019 January 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
associated mortality by year and influenza type/subtype; however, our estimates are very 
similar to those previously published. For example, in children aged <5 years, we estimated 
a mean annual seasonal influenza- and RSV-associated all-respiratory death rate (per 100 
000 population) of 10 (95% CI: 7–13) and 13 (95% CI: 2–19), respectively, compared to 8 
(95% CI: 4–13) and 10 (95%: CI 5–15) estimated for the period 1998–2009. Similarly, in 
individuals aged ≥5 years we estimated an annual average seasonal influenza- and RSV-
associated all-respiratory death rate (per 100 000 population) of 8 (95% CI: 4–11) and 2 
(95% CI: 1–8) compared to 8 (95% CI: 6–12) and 1 (95% CI: 0–1) estimated for the period 
1998–2009. Differences in the modeling approach used have been found to be less important 
than seasonal variation in disease burden in other settings [16]. There has been an overall 
decreasing mortality in children and adults in South Africa since 2006 largely as a result of 
interventions for prevention and treatment of HIV, and this has likely been associated with 
decreases in influenza- and RSV-associated mortality [7, 17]. Our previous study included a 
long period from the early years of the HIV epidemic where mortality was lower than in 
recent years through the peak in HIV-associated mortality [5, 6]. The present analysis 
included 5 years in the period of decreasing mortality following widespread HIV 
interventions, but mortality has still not reduced to the levels seen in the early HIV epidemic. 
This likely contributed to the overall similar estimated excess mortality levels. An analysis 
of a longer time series including data from the early, peak, and post-peak periods of the HIV 
epidemic, and incorporating a consistent modeling approach to account for the estimated 
contribution of HIV to mortality would be useful to directly address the impact of the HIV 
epidemic on absolute and proportionate influenza- and RSV-associated mortality burden [6, 
18].
The highest burden of influenza-associated mortality is in adults aged ≥65 years, similar to 
other countries [11, 15, 19, 20]. In addition, we found a substantial mortality burden in 
children aged <5 years, particularly those aged <1 year and in adults aged 20–64 years for 
all-cause and all-respiratory cause of death groups. HIV infection is an important driver of 
this mortality, particularly in young adults [3–6]. In young children, high baseline mortality 
rates likely contribute to the high mortality burden, fueled by the presence of underlying 
conditions such as malnutrition and challenges in accessing care [3, 4, 21]. The majority of 
influenza-associated cardiovascular deaths were in individuals aged ≥65 years, likely 
reflecting the prevalence of underlying cardiac illness in this older population [22].
The highest RSV-associated mortality burden was in children aged <5 years, particularly 
those aged <1 year. This is in keeping with other studies from South Africa and elsewhere 
[18, 19, 23]. An increase in RSV-associated mortality was also observed in the elderly but to 
a lower extent than for influenza [6]. Importantly, in South Africa, the influenza and RSV 
seasons occur at different times of the year, and so it is possible to separately estimate the 
relative contributions of influenza and RSV to mortality more robustly than in settings where 
influenza and RSV co-circulate. We were not powered to evaluate the impact of the 
separation in timing of influenza and RSV outbreaks on excess mortality estimates as we 
only had 5 years of available data.
We estimated 3460 (95% CI: 3010–6572) influenza-associated all-cause deaths in the first 
wave of the influenza A(H1N1)pdm09 pandemic and 10 753 (2922–14 489) and 5938 
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(2465–8573) in the 2nd and 3rd waves, respectively. Although mortality point estimates 
were higher for the 2nd and 3rd waves compared to the 1st wave, they were within the range 
of mortality seen for seasonal influenza. We observed a marked shift in the age distribution 
of influenza A(H1N1)pdm09-associated mortality from the first wave which predominantly 
affected young and middle-aged adults to the second and third waves where mortality was 
concentrated in the extremes of age. This shift in age distribution has been described in other 
settings and likely contributed to the higher mortality in the second and third waves [24–26]. 
Postulated reasons for the shift in age distribution include increasing immunity in younger 
individuals and gradual drift of the virus. The timing of the first wave at the end of the 
influenza season in 2009 may also have contributed to a shorter epidemic duration in this 
year. In order to fully estimate the impact of the first wave of the pandemic, years of life lost 
might be a more robust measure [11].
We estimate that in South Africa more than half of all influenza- and adult RSV-associated 
deaths occur outside of the hospital. Strikingly, amongst children aged <5 years there was a 
difference in the location of influenza- and RSV-associated deaths with RSV-associated 
deaths occurring predominantly in-hospital and influenza-associated deaths occurring 
predominantly outside of the hospital. A contributing factor could be the fact that RSV 
predominantly affects infants aged <6 months, whereas influenza is more common in 
slightly older children [27]. Very young children may be more likely to be brought to 
hospital and to be admitted to hospital. Among hospitalized children aged <5 years with 
respiratory illness in South Africa, approximately 26% test positive for RSV and 7% test 
positive for influenza [27]. In contrast, our estimates of respiratory mortality in children 
aged <5 years were relatively similar for RSV (665; 95% CI: 105–1021) and influenza (508; 
95% CI: 368–693). Although a high in-hospital case-fatality ratio for influenza compared to 
RSV may partly explain this difference, the substantial burden of influenza-associated 
mortality outside of the hospital may be an important additional contributing factor [3, 28].
In a study from Canada, with 70% influenza vaccine coverage in the community dwelling 
elderly, 57% percent of influenza-associated deaths (mainly in the elderly) occurred out-of-
hospital, with 73% of deaths in those aged >90 years occurring out of hospital [23]. A high 
proportion of individuals dying of influenza had underlying lung or heart disease and sudden 
death due to a cardiac event may be more likely to occur out of hospital. It has been 
suggested that the South African elderly may be less likely to seek healthcare than younger 
individuals, although there are no published studies of health-seeking behavior in this age 
group [4]. Patients may be less likely to be admitted during peak influenza season as 
facilities may be full.
In the first wave of the 2009 pandemic we observed that influenza A(H1N1)pdm09-
associated deaths were more likely to occur in-hospital, in contrast to the observation that 
seasonal influenza-associated deaths were more likely out of the hospital. Heightened 
awareness during the pandemic could have led to patients seeking care more expeditiously, 
although there were no available data from South Africa on health seeking or hospital 
procedures during the pandemic [29]. The age-shift in mortality away from the extremes of 
age may also have contributed as young adults may be more likely to seek care than the 
elderly [3].
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Our study has several limitations. Although we used established modeling approaches to 
estimate influenza- and RSV-associated mortality, the data are ecologic and individuals were 
not tested for influenza. Approximately 13% of deaths were nonspecifically coded, and this 
percentage remained constant over the study period. There are no available data on 
reliability of classification of cause of death for in- and out-of-hospital deaths, but 
misclassification may be more likely for out-of-hospital deaths because when deaths occur 
in remote areas a tribal leader may complete the death certificate [30]. For this reason, we 
restricted the analysis of in-and out-of-hospital deaths to large cause of death groups such as 
respiratory and circulatory deaths. All-cause deaths should not be subject to this bias, and 
trends in in- and out-of-hospital mortality were similar for all-cause deaths. Weekly data on 
cause of death were only available from 2009 onward limiting the number of years of data 
available for inclusion. Since 2000, completeness of death registration in South Africa is 
estimated to exceed 95%, but estimates of completeness are not available for in- and out-of-
hospital deaths separately [31]. Confidence intervals were estimated using bootstrap 
analysis, and we obtained wide confidence intervals for some estimates particularly for age 
groups and endpoints with small numbers.
Influenza and RSV cause substantial mortality in South Africa, a large proportion of which 
occurs out of the hospital. The mortality burden of influenza A(H1N1)pdm09 was greater in 
the second and third waves, accompanied by a marked shift in age distribution of deaths. 
These findings will be helpful to inform our understanding of global and regional mortality 
burden and for pandemic planning.
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Figure 1. 
A, Detection rate (i.e., weekly number of positive specimens divided by annual number of 
specimens tested) of influenza (by type/subtype) and respiratory syncytial virus (all ages), 
Severe Acute Respiratory Illness Surveillance (SARI) programme, South Africa, 2009–
2013. B, Number of deaths in- and out-of-hospital by year and week, children aged <5 years, 
South Africa, 2009–2013. C, Number of deaths in- and out-of-hospital by year and week, 
individuals aged ≥5 years, South Africa, 2009–2013.
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Figure 2. 
Ratio of the proportion of influenza A(H1N1)pdm09-associated deaths in each age group in 
2011 (2nd wave) and 2013 (3rd wave) vs 2009 (1st wave)*. A, All-cause; B, All-circulatory; 
C, All-respiratory; D, Pneumonia and influenza. Proportionate mortality ratio = (number of 
influenza A(H1N1)pdm09-associated deaths in age group i in 2011 or 2013/total influenza 
A(H1N1)pdm09-associated deaths in 2011 or 2013)/(number of influenza A(H1N1)pdm09-
associated deaths in age group i in 2009/total influenza A(H1N1)pdm09-associated deaths in 
2009).
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Table 1
Estimated Mean Annual Rate of RSV- and Seasonal Influenza-associated Excess Deaths by Cause of Death 
and Age Group in South Africa, 2009–2013
Cause of death
Cause of death
All-causes,
Ratea (95% CI)b
All-circulatory,
Ratea (95% CI)b
All-respiratory,
Ratea (95% CI)b
Pneumonia and influenza,
Ratea (95% CI)b
RSV
<1 143.4 (0.0–195.4) 1.5 (0.0–6.8) 42.0 (0.0–63.9) 30.4 (0.0–42.1)
1–4 7 (3.9–17.0) 0.3 (0.0–1.3) 5 (2.5–7.9) 3.3 (2.2–5.8)
5–19 3.7 (2.5–8.4) 0.6 (0.2–0.9) 0.6 (0.3–1.4) 0.6 (0.1–1.0)
20–44 9.9 (5.5–26.0) 0.8 (0.6–2.7) 1.2 (0.4–4.6) 0.9 (0.2–4.1)
45–64 15.7 (10.4–53.6) 4.5 (3.7–16.4) 4.6 (2.7–14.3) 2.4 (1.1–6.8)
65–74 22 (14.5–67.6) 8.4 (5.5–30.7) 4.2 (0.0–34.3) 5.1 (1.1–17.7)
≥75 81.7 (72.7–339.5) 41.3 (36.0–189.1) 16 (13.0–88.1) 15.7 (6.4–67.4)
<5 35.2 (3.1–53.8) 0.6 (0.0–2.5) 12.7 (2.0–19.4) 8.9 (1.8–13.3)
≥5 10.7 (6.8–31.5) 2.4 (1.8–8.5) 2.0 (0.9–7.7) 1.5 (0.4–5.1)
All ages 13.2 (6.4–33.8) 2.2 (1.6–7.9) 3.1 (1.0–8.9) 2.2 (0.6–5.9)
Influenza
<1 87.3 (58.2–118.6) 2.2 (1.2–4.5) 33.6 (25.7–45.1) 25.4 (18.3–34.6)
1–4 6.8 (2.8–8.9) 0.8 (0.3–1.5) 3.4 (2.1–4.9) 2.8 (2.1–4.1)
5–19 2.7 (1.2–3.7) 0.2 (0.1–0.4) 0.8 (0.5–1.2) 0.6 (0.3–1.0)
20–44 15.4 (7.4–22.6) 1.3 (0.4–2.3) 4.4 (2.1–7.6) 2.9 (1.4–5.2)
45–64 34.3 (14.8–46.3) 10.7 (3.3–14.8) 13.9 (6.9–18.7) 6.6 (3.9–9.7)
65–74 73.5 (34.5–98.1) 34.2 (16.7–47.1) 27.8 (19.0–38.0) 11.7 (5.7–16.0)
≥75 386 (193.4–473.1) 183.9 (81.2–224.7) 115.7 (36.1–140.9) 79.5 (44.5–94.2)
<5 23.4 (14.2–31.6) 1.1 (0.5–2.1) 9.7 (7.0–13.2) 7.5 (5.5–10.4)
≥5 22.9 (10.7–30.5) 6.9 (2.8–9.1) 7.6 (3.6–10.7) 4.4 (2.3–6.4)
All ages 23.0 (11.0–30.6) 6.3 (2.5–8.4) 7.8 (3.9–10.9) 4.7 (2.7–6.8)
Abbreviations: CI, confidence interval; RSV, respiratory syncytial virus.
a
Death rates per 100 000 person-years.
b95% confidence intervals estimated using bootstrap resampling on blocks of calendar years over 1000 replications.
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